I would like to deduce why the collaboration between Amyris and Biomillenia, announced on January 8, 2021, could be important.
Future synthetic biology is not about the lab scale development of a first strain, but more about advanced metabolic engineering leading to improved industrial scale strains able to produce the molecule in high yields in large-scale reactors, taking account of all possible parameters, promoters and switches.
The goal is a production strain with high process stability and performance metrics such as longer fermentation cycles, resistance to mutations, toxity and low susceptibility to stress (change in nutritions and conditions).